The global peptide therapeutics market size was valued at $33.3 billion in 2021, and is projected to reach $64.3 billion by 2031, growing at a CAGR o ...

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somato ...

In January, Takeda said revenue was up 9.8% from the same period a year prior in its fiscal Q3 2024, which ended on December 31 of last year. The company is planning to publish its fiscal-year 2024 ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 ...

TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...

Takeda's Q3 profits take a hit due to new generic ADHD drugs A 'behind the scenes' woman rises to the top at Takeda A 'behind the scenes' woman rises to the top at Takeda Alexandria sells Andover ...

Thank you very much for joining us for Takeda’s FY 2023 Q3 Earnings Announcement despite your busy schedule. And I’m emcee today. I’m O’Reilly, Head of IR. First of all, I would like to ...

Takeda chief financial officer, Costa Saroukos, commented: “In FY2023 Q3 we made further progress in our vision to discover and deliver life-transforming treatments, receiving two new U.S. FDA ...

As a result, Takeda is taking a 74 billion yen—or $770.5 million—write-down. However, at the top of the Q3 loser’s column is Sanofi. Just days before Halloween, the French drugmaker spooked investors ...

Narrow-moat Takeda’s third-quarter fiscal result was in line with our expectations after adjusting for currency tailwinds due to a depreciating Japanese yen. Revenue was JPY 1,096.6 billion ...